Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Oncogenic Ras proteins are key drivers in many cancers, but their specific effector pathways essential for tumor initiation and maintenance remain unclear.
• Developing effective therapeutics against Ras-driven cancers requires understanding the precise molecular mechanisms and potential resistance pathways.

Purpose of the Study:

• To investigate the roles of PI3 kinase/Akt and Raf/MEK/ERK signaling pathways in K-Ras-driven T-cell acute lymphoblastic leukemia (T-ALL).
• To explore the mechanisms by which leukemia cells overcome impaired Ras effector signaling and develop resistance to targeted therapies.

Main Methods:

• Expression of oncogenic K-Ras(D12) with impaired signaling in bone marrow cells, followed by transplantation into recipient mice to induce T-ALL.
• Analysis of acquired mutations, gene silencing (e.g., PTEN), and signaling pathway activation (e.g., phosphorylated Akt) in T-ALL cells.
• Assessment of T-ALL cell line resistance to the MEK inhibitor PD0325901.

Main Results:

• Defective K-Ras oncoproteins initiated aggressive T-ALL despite attenuated signaling.
• Leukemia cells acquired secondary mutations or silenced PTEN to restore Ras activity and overcome impaired PI3K/Akt and Raf/MEK/ERK signaling.
• PTEN-deficient T-ALL cells exhibited elevated Akt phosphorylation, a gene expression profile resembling human early T-cell precursor ALL, and resistance to MEK inhibition.

Conclusions:

• Both PI3 kinase/Akt and Raf/MEK/ERK pathways are critical for aberrant growth in T-ALL, driven by oncogenic Ras.
• Leukemia cells exhibit strong selective pressure to overcome targeted inhibition, employing diverse mechanisms to develop resistance in vivo.